Last reviewed · How we verify
placebo/valsartan
Valsartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure.
Valsartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.
At a glance
| Generic name | placebo/valsartan |
|---|---|
| Also known as | Valsartan, Other names:, Diovan, Axudan, Vanatex |
| Sponsor | Medical University of Silesia |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation and reduces sodium and water retention, thereby decreasing blood pressure and cardiac workload. This mechanism also provides cardioprotective and renoprotective effects in hypertension and heart failure.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction with left ventricular dysfunction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Headache
Key clinical trials
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (PHASE1)
- The ENCHANTMENT HIV Study (PHASE2)
- A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (PHASE2)
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction (PHASE2)
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo/valsartan CI brief — competitive landscape report
- placebo/valsartan updates RSS · CI watch RSS
- Medical University of Silesia portfolio CI